Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Rhea-AI Summary

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological prescription products, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.

President and CEO Claude Maraoui will lead a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. Investors can access the fireside chat webcast on Journey Medical's website investor section for approximately 30 days following the event.

News Market Reaction – DERM

+3.11%

1 alert

+3.11% News Effect

On the day this news was published, DERM gained 3.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37^th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California.

Claude Maraoui, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference.

A webcast of the company’s fireside chat will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

When is Journey Medical (DERM) presenting at the ROTH Conference 2025?

Journey Medical will present on Tuesday, March 18, 2025, at 12:30 p.m. PT during a fireside chat at the 37th Annual ROTH Conference in Dana Point, California.

How can investors watch Journey Medical's (DERM) ROTH Conference presentation?

Investors can watch the webcast on Journey Medical's website (journeymedicalcorp.com) in the Investors section under News and Events for approximately 30 days after the conference.

What type of meetings will Journey Medical (DERM) conduct at the ROTH Conference 2025?

Journey Medical's management will participate in a fireside chat and will be available for one-on-one meetings throughout the conference.

Who will represent Journey Medical (DERM) at the 2025 ROTH Conference?

Claude Maraoui, President and Chief Executive Officer of Journey Medical, will represent the company at the conference.